Redundant enhancers and causal variants in the TCF7L2 gene.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Transcription Factor-7-Like-2 (TCF7L2) in Atherosclerosis: A Potential Biomarker and Therapeutic Target.Frontiers in cardiovascular medicine · 2021
   Review
2. Admixture mapping and fine-mapping of type 2 diabetes susceptibility loci in African American women.Journal of human genetics · 2018
   Article
3. Enhancers and super-enhancers have an equivalent regulatory role in embryonic stem cells through regulation of single or multiple genes.Genome research · 2017
   Article
4. Multiethnic genome-wide association study identifies ethnic-specific associations with body mass index in Hispanics and African Americans.BMC genetics · 2016
   Article
5. Rare intronic variants of TCF7L2 arising by selective sweeps in an indigenous population from Mexico.BMC genetics · 2016
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as